Analysts See $0.29 EPS for Horizon Pharma Public Limited Company (HZNP); Nuveen Diversified Dividend & Income Fund (JDD) Sentiment Is 1.86

July 25, 2018 - By Lisa Delgado

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Logo

Nuveen Diversified Dividend & Income Fund (JDD) investors sentiment increased to 1.86 in Q1 2018. It’s up 1.36, from 0.5 in 2017Q4. The ratio is more positive, as 13 active investment managers increased and opened new holdings, while 7 decreased and sold their stakes in Nuveen Diversified Dividend & Income Fund. The active investment managers in our database now possess: 1.08 million shares, down from 1.26 million shares in 2017Q4. Also, the number of active investment managers holding Nuveen Diversified Dividend & Income Fund in top ten holdings was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 4 Increased: 10 New Position: 3.

Analysts expect Horizon Pharma Public Limited Company (NASDAQ:HZNP) to report $0.29 EPS on August, 8 before the open.They anticipate $0.12 EPS change or 29.27% from last quarter’s $0.41 EPS. HZNP’s profit would be $47.86 million giving it 15.09 P/E if the $0.29 EPS is correct. After having $0.03 EPS previously, Horizon Pharma Public Limited Company’s analysts see 866.67% EPS growth. The stock increased 1.33% or $0.23 during the last trading session, reaching $17.5. About 794,487 shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has risen 62.19% since July 25, 2017 and is uptrending. It has outperformed by 49.62% the S&P500. Some Historical HZNP News: 01/05/2018 – Horizon Pharma plc to Participate in the UBS Global Healthcare Conference; 08/05/2018 – Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Cover; 21/05/2018 – Horizon Pharma Presenting at UBS Conference Tomorrow; 09/05/2018 – Horizon Pharma 1Q Loss $157.3M; 08/05/2018 – HORIZON PHARMA GETS 2 NOTICES OF ALLOWANCE ON RAVICTI PATENTS; 09/05/2018 – Horizon Pharma 1Q Loss/Shr 96c; 17/04/2018 – Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications; 09/05/2018 – HORIZON PHARMA 1Q ADJ EPS 3C, EST. 6C; 26/03/2018 – STAT Plus: Canada probes Horizon Pharma over efforts to boost sales of a rare disease drug; 03/05/2018 – Horizon Pharma plc Announces Sangita Iyer as a 2018 Healthcare Businesswomen’s Association Rising Star

More news for Horizon Pharma Public Limited Company (NASDAQ:HZNP) were recently published by: Nasdaq.com, which released: “7 Healthcare Stocks That Are Coming to Life” on July 23, 2018. Streetinsider.com‘s article titled: “UPDATE: Horizon Pharma (HZNP) Announces USPTO Issuance of Additional Notices of Allowance With Claims …” and published on July 16, 2018 is yet another important article.

Since May 25, 2018, it had 0 buys, and 3 selling transactions for $1.91 million activity. $1.35M worth of Horizon Pharma Public Limited Company (NASDAQ:HZNP) shares were sold by Walbert Timothy P. $271,249 worth of Horizon Pharma Public Limited Company (NASDAQ:HZNP) was sold by Beeler Brian K on Friday, June 8.

Investors sentiment increased to 1.38 in Q1 2018. Its up 0.34, from 1.04 in 2017Q4. It improved, as 12 investors sold Horizon Pharma Public Limited Company shares while 53 reduced holdings. 36 funds opened positions while 54 raised stakes. 127.87 million shares or 0.61% less from 128.65 million shares in 2017Q4 were reported. First Tru L P holds 136,717 shares or 0% of its portfolio. Da Davidson stated it has 10,085 shares. Vanguard Group stated it has 0.01% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Legal General Group Pcl holds 61,069 shares. Lakeview Capital Lc invested in 0.3% or 27,629 shares. Nomura Holding holds 0% or 54,916 shares. Financial Bank Of Montreal Can has invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Point72 Asia (Hong Kong) holds 1,377 shares. Jane Street Group Ltd Com owns 12,471 shares. Tekla Management Ltd Liability reported 0.09% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Fmr Limited Liability Company holds 0% or 484,296 shares. Adams Diversified Equity Fund Inc holds 0.03% or 37,000 shares. Eqis Cap Management invested in 0.01% or 13,712 shares. Barclays Public Limited accumulated 216,437 shares. Signaturefd Limited Liability Com holds 46 shares or 0% of its portfolio.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $2.89 billion. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Among 8 analysts covering Horizon Pharma Inc (NASDAQ:HZNP), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Horizon Pharma Inc had 11 analyst reports since January 30, 2018 according to SRatingsIntel. The company was maintained on Monday, June 18 by Stifel Nicolaus. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Buy” rating given on Sunday, April 15 by Cantor Fitzgerald. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Buy” rating given on Thursday, March 1 by UBS. The firm has “Buy” rating by Cowen & Co given on Wednesday, February 28. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Buy” rating given on Wednesday, February 28 by Cantor Fitzgerald. As per Monday, May 7, the company rating was maintained by Mizuho. The firm earned “Buy” rating on Wednesday, February 28 by Piper Jaffray. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, March 2 report. Citigroup downgraded Horizon Pharma Public Limited Company (NASDAQ:HZNP) on Wednesday, June 27 to “Neutral” rating. Mizuho maintained the stock with “Buy” rating in Wednesday, April 11 report.

Nuveen Diversified Dividend and Income Fund is a closed-ended balanced mutual fund launched by Nuveen Investments Inc. The company has market cap of $222.10 million. The fund is co-managed by Nuveen Fund Advisors, LLC, NWQ Investment Management Company, LLC, Security Capital Research & Management Incorporated, Symphony Asset Management LLC, and Wellington Management Company LLP. It has a 10.14 P/E ratio. It invests in public equity and fixed income markets across the globe.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: